These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

390 related items for PubMed ID: 27710871

  • 1. Trabectedin as a chemotherapy option for patients with BRCA deficiency.
    Monk BJ, Lorusso D, Italiano A, Kaye SB, Aracil M, Tanović A, D'Incalci M.
    Cancer Treat Rev; 2016 Nov; 50():175-182. PubMed ID: 27710871
    [Abstract] [Full Text] [Related]

  • 2. Trabectedin: Ecteinascidin 743, Ecteinascidin-743, ET 743, ET-743, NSC 684766.
    Drugs R D; 2006 Nov; 7(5):317-28. PubMed ID: 16922593
    [Abstract] [Full Text] [Related]

  • 3. Trabectedin as a new chemotherapy option in the treatment of relapsed platinum sensitive ovarian cancer.
    Monk BJ, Dalton H, Benjamin I, Tanović A.
    Curr Pharm Des; 2012 Nov; 18(25):3754-69. PubMed ID: 22591421
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Effect of BRCA1 and XPG mutations on treatment response to trabectedin and pegylated liposomal doxorubicin in patients with advanced ovarian cancer: exploratory analysis of the phase 3 OVA-301 study.
    Monk BJ, Ghatage P, Parekh T, Henitz E, Knoblauch R, Matos-Pita AS, Nieto A, Park YC, Cheng PS, Li W, Favis R, Ricci D, Poveda A.
    Ann Oncol; 2015 May; 26(5):914-920. PubMed ID: 25722380
    [Abstract] [Full Text] [Related]

  • 6. The efficacy of trabectedin in treating ovarian cancer.
    Teplinsky E, Herzog TJ.
    Expert Opin Pharmacother; 2017 Feb; 18(3):313-323. PubMed ID: 28140689
    [Abstract] [Full Text] [Related]

  • 7. Unique features of trabectedin mechanism of action.
    Larsen AK, Galmarini CM, D'Incalci M.
    Cancer Chemother Pharmacol; 2016 Apr; 77(4):663-71. PubMed ID: 26666647
    [Abstract] [Full Text] [Related]

  • 8. Prospective phase II trial of trabectedin in BRCA-mutated and/or BRCAness phenotype recurrent ovarian cancer patients: the MITO 15 trial.
    Lorusso D, Scambia G, Pignata S, Sorio R, Amadio G, Lepori S, Mosconi A, Pisano C, Mangili G, Maltese G, Sabbatini R, Artioli G, Gamucci T, Di Napoli M, Capoluongo E, Ludovini V, Raspagliesi F, Ferrandina G.
    Ann Oncol; 2016 Mar; 27(3):487-93. PubMed ID: 26681678
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Focus on Trabectedin in Ovarian Cancer: What Do We Still Need to Know?
    Boccia SM, Sassu CM, Ergasti R, Vertechy L, Apostol AI, Palluzzi E, Fagotti A, Scambia G, Marchetti C.
    Drug Des Devel Ther; 2024 Mar; 18():2021-2032. PubMed ID: 38863768
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Trabectedin mechanism of action and platinum resistance: molecular rationale.
    Ray-Coquard I.
    Future Oncol; 2017 Oct; 13(23s):17-21. PubMed ID: 29020822
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Biology of ovarian cancer and trabectedin mechanism of action.
    Ray-Coquard I.
    Future Oncol; 2013 Dec; 9(12 Suppl):11-7. PubMed ID: 24195525
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Trabectedin for the treatment of breast cancer.
    D'Incalci M, Zambelli A.
    Expert Opin Investig Drugs; 2016 Dec; 25(1):105-15. PubMed ID: 26592307
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Trabectedin in patients with advanced non-small-cell lung cancer (NSCLC) with XPG and/or ERCC1 overexpression and BRCA1 underexpression and pretreated with platinum.
    Massuti B, Cobo M, Camps C, Dómine M, Provencio M, Alberola V, Viñolas N, Rosell R, Tarón M, Gutiérrez-Calderón V, Lardelli P, Alfaro V, Nieto A, Isla D.
    Lung Cancer; 2012 Jun; 76(3):354-61. PubMed ID: 22197612
    [Abstract] [Full Text] [Related]

  • 20. Trabectedin for the treatment of relapsed ovarian cancer.
    Papaioannou D, Rafia R, Stevenson MD, Stevens JW, Evans P.
    Health Technol Assess; 2011 May; 15 Suppl 1():69-75. PubMed ID: 21609655
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.